60¢sixtycents

PepGen Inc.PEPG

$1.79+0.09 (+5.29%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$76M
Micro-cap
-77%
2022 — today
10-Year Price
-89%
2022 — today
52-Week Range
$1.01$7.17
Current $1.79· 13%

PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.

Valuation in context

P/E ratio
-0.9
N/A
Not meaningful — company is unprofitable
P/B ratio
0.6
Historically cheap
Historically cheap relative to the last 10 years
FCF Yield
-102.2%
Historically low
Historically low relative to the last 10 years
Free · No credit card needed

Get alerted when PEPG is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.